Vogel G, Stürzebecher J, Klessen C, Lauten G
Folia Haematol Int Mag Klin Morphol Blutforsch. 1982;109(1):115-20.
The kallikrein specific chromogenic peptide substrates S-2302 (KABI) and Chromozym PK (Boehringer) were used in the first analysis of a familial defect in the early stage of clotting. Slight to extensive prolongation of the activated partial thromboplastin time was seen in the affected persons. Using dextransulfate for activation of plasma marked deficiency in kallikrein activity was found in 3 persons. Using factor XIIa (activated Hageman factor) for activation normal prekallikrein levels were found in 2 of them whereas factor XII levels, however, were below normal. The third had a prekallikrein deficiency presumably caused by oral contraceptives. In a fourth member of the family factor XII deficiency was found with normal kallikrein activity. The application of chromogenic peptide substrates for analysing the early stage of clotting has to take into account the special mechanisms of activation.
在对凝血早期家族性缺陷的首次分析中,使用了激肽释放酶特异性显色肽底物S - 2302(卡比公司)和Chromozym PK(勃林格公司)。在受影响的个体中,活化部分凝血活酶时间出现了轻度至显著延长。使用硫酸葡聚糖激活血浆后,在3名个体中发现激肽释放酶活性明显缺乏。使用因子XIIa(活化的哈格曼因子)激活后,其中2人的前激肽释放酶水平正常,然而因子XII水平低于正常。第三人存在前激肽释放酶缺乏,推测是由口服避孕药引起的。在该家族的第四名成员中,发现因子XII缺乏,但激肽释放酶活性正常。使用显色肽底物分析凝血早期时,必须考虑激活的特殊机制。